HLB Therapeutics.
₩8,960
2
-₩20-0.22% Today
Statistics
Day High
9,110
Day Low
8,650
52W High
17,700
52W Low
2,840.58
Volume
613,282
Avg. Volume
1,839,355
Mkt Cap
635.83B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
13MayExpected
Expected EPS
N/A
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow 115450.KQ. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Seegene
096530.KQ
Mkt Cap970.44B
Celltrion Health Care
091990.KQ
Mkt Cap11.33T
Access Bio
950130.KQ
Mkt Cap209.63B
About
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
Show more...
CEO
Mr. Doug Jang
Country
KR
ISIN
KR7115450009